STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio (BBIO) CEO-linked family trusts sell 80,000 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. director and CEO Neil Kumar reported that entities associated with him sold a total of 80,000 shares of Common Stock of BBIO in open‑market transactions on April 9–10, 2026. The trades were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co‑trustee, at prices in the mid‑$70s per share.

The filing states these sales were made under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and includes a disclaimer that Kumar does not admit beneficial ownership of the trust shares beyond any pecuniary interest. After the transactions, the trusts and Kumar’s direct account together still hold several million shares.

Positive

  • None.

Negative

  • None.
Insider Kumar Neil
Role Chief Executive Officer
Sold 80,000 shs ($5.97M)
Type Security Shares Price Value
Sale Common Stock 20,000 $74.6048 $1.49M
Sale Common Stock 20,000 $74.6038 $1.49M
Sale Common Stock 7,200 $73.6444 $530K
Sale Common Stock 5,300 $74.6044 $395K
Sale Common Stock 7,500 $75.5548 $567K
Sale Common Stock 7,072 $73.6427 $521K
Sale Common Stock 5,128 $74.5669 $382K
Sale Common Stock 7,800 $75.5287 $589K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 595,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 4,398,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 234,451 shares (Direct)
Footnotes (10)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
  2. F2. Represents the weighted average sale price of the shares sold from $73.19 to $74.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  3. F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  4. F4. Represents the weighted average sale price of the shares sold from $74.19 to $75.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  5. F5. Represents the weighted average sale price of the shares sold from $75.22 to $76.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  6. F6. Represents the weighted average sale price of the shares sold from $73.15 to $74.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  7. F7. Represents the weighted average sale price of the shares sold from $74.18 to $75.145 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  8. F8. Represents the weighted average sale price of the shares sold from $75.18 to $76.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  9. F9. Represents the weighted average sale price of the shares sold from $74.26 to $75.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  10. F10. Represents the weighted average sale price of the shares sold from $74.27 to $75.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Total shares sold 80,000 shares Aggregate open-market sales on April 9–10, 2026
Sale price example $74.6048 per share 20,000-share sale on April 10, 2026 by irrevocable trust
Irrevocable trust holdings 595,686 shares Kumar Haldea Family Irrevocable Trust after April 10, 2026 trades
Revocable trust holdings 4,398,447 shares Kumar Haldea Revocable Trust after April 10, 2026 trades
Direct holdings 234,451 shares Neil Kumar’s directly held BBIO common stock after April 9, 2026
Net insider share change -80,000 shares Net-sell direction from transaction summary
Rule 10b5-1 sales plan financial
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."
weighted average sale price financial
"Represents the weighted average sale price of the shares sold from $73.19 to $74.16 per share."
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any,"
beneficial ownership financial
"this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider activity did BridgeBio Pharma (BBIO) disclose in this Form 4?
BridgeBio Pharma’s Form 4 shows entities associated with CEO Neil Kumar sold 80,000 shares of BBIO common stock in open-market trades on April 9–10, 2026, through family trusts where he serves as co-trustee, at prices in the mid-$70s per share.

Were the BBIO insider share sales by Neil Kumar pre-planned under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 sales plan adopted by Neil Kumar on March 31, 2025. Such plans schedule trades in advance, making the timing more routine rather than a reaction to short-term market or company developments.

How many BridgeBio (BBIO) shares were sold and at what prices?
The Form 4 reports aggregate sales of 80,000 BBIO common shares. Individual transaction lines show weighted average sale prices generally between about $73 and $76 per share, reflecting multiple small open-market blocks executed over April 9 and April 10, 2026.

How many BBIO shares do the trusts associated with Neil Kumar hold after these sales?
After the disclosed transactions, the Kumar Haldea Family Irrevocable Trust holds 595,686 BBIO shares, while the Kumar Haldea Revocable Trust holds 4,398,447 shares. These figures indicate the reported 80,000-share sale represents a relatively small portion of the trusts’ combined holdings.

Does Neil Kumar personally own BBIO shares outside the family trusts?
Yes. The Form 4 includes a direct ownership entry showing 234,451 BBIO common shares held directly after the reported activity. This is separate from the larger positions held by the family irrevocable and revocable trusts where he acts as co-trustee.

How does the Form 4 describe Neil Kumar’s beneficial ownership of BBIO trust shares?
A footnote states that Neil Kumar disclaims beneficial ownership of the trust-held shares except to the extent of his pecuniary interest, if any. The report clarifies that it should not be considered an admission that he beneficially owns those shares for Section 16 or any other purpose.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Neil
(Last)(First)(Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/09/2026S(1)7,200D$73.6444(2)628,486IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/09/2026S(1)5,300D$74.6044(4)623,186IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/09/2026S(1)7,500D$75.5548(5)615,686IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/09/2026S(1)7,072D$73.6427(6)4,431,375IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/09/2026S(1)5,128D$74.5669(7)4,426,247IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/09/2026S(1)7,800D$75.5287(8)4,418,447IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/10/2026S(1)20,000D$74.6048(9)595,686IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock04/10/2026S(1)20,000D$74.6038(10)4,398,447IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock234,451D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
2. Represents the weighted average sale price of the shares sold from $73.19 to $74.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
4. Represents the weighted average sale price of the shares sold from $74.19 to $75.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. Represents the weighted average sale price of the shares sold from $75.22 to $76.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. Represents the weighted average sale price of the shares sold from $73.15 to $74.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
7. Represents the weighted average sale price of the shares sold from $74.18 to $75.145 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
8. Represents the weighted average sale price of the shares sold from $75.18 to $76.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
9. Represents the weighted average sale price of the shares sold from $74.26 to $75.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
10. Represents the weighted average sale price of the shares sold from $74.27 to $75.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Remarks:
/s/ Will Solis, Attorney-in-Fact04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR